8-K/A: TransCode Therapeutics Faces Nasdaq Listing Deficiency

TransCode Therapeutics has received a deficiency letter from Nasdaq for failing to meet the minimum stockholders equity requirement and is developing a plan to regain compliance.

Summary

• TransCode Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, indicating non-compliance with the minimum stockholders equity requirement of $2,500,000.
• As of March 31, 2026, the company's stockholders equity was reported as $1,251,427, falling below the Nasdaq threshold.
• The company has 45 days, until July 3, 2026, to submit a plan to regain compliance.
• The compliance plan is expected to involve stockholder approval for the conversion of Series A Non-Voting Convertible Preferred Stock.
• If stockholder approval is not obtained by December 31, 2026, holders of Series A Preferred Stock may elect to have their shares redeemed.
• The Series A Preferred Stock is currently classified under temporary equity due to this redemption feature.
• Reclassification of Series A Preferred Stock to equity after stockholder approval would lead to regaining compliance.
• There is a risk that Nasdaq may not accept the compliance plan or that the company may fail to regain compliance within any granted extension period.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a negative development due to the Nasdaq deficiency, but the presence of a clear plan and the potential for resolution through stockholder action mitigates extreme negativity.

Positives

• The company has a clear plan to address the Nasdaq deficiency, centered on stockholder approval for preferred stock conversion.
• A preliminary proxy for the stockholder meeting was filed on May 8, 2026, indicating proactive steps.
• The notification from Nasdaq does not have an immediate effect on the company's listing.
• The company has a defined period (until July 3, 2026) to submit its compliance plan.

Negatives

• The company's stockholders equity of $1,251,427 as of March 31, 2026, is significantly below the Nasdaq requirement of $2,500,000.
• Failure to regain compliance could lead to delisting from the Nasdaq Capital Market, which would have a material adverse effect.
• There is a risk that stockholders may not approve the conversion of Series A Preferred Stock.
• If approval is not obtained, the Series A Preferred Stock may be redeemed, impacting the company's equity structure.

Risks

• Nasdaq may not accept the company's plan to regain compliance with the Stockholders Equity Requirement.
• The company may be unable to evidence compliance within any extension period granted by Nasdaq.
• Failure to regain compliance could result in the delisting of the company's common stock from Nasdaq.
• Delisting would have a material adverse effect on the company's operations, reputation, and share value.
• The redemption feature of the Series A Preferred Stock introduces uncertainty regarding its classification and impact on equity.
• The company may not obtain the necessary stockholder approval for the conversion of Series A Preferred Stock by December 31, 2026.

Future Outlook

The company expects to regain compliance with the Nasdaq Stockholders Equity Requirement through stockholder approval of the conversion of Series A Preferred Stock. The company is working on a compliance plan to be submitted to Nasdaq by July 3, 2026. A definitive proxy statement will be filed with the SEC regarding proposals for conversion of preferred stock and other matters.

Management Comments

• The Company expects to include in its Compliance Plan that the Company expects to regain compliance with the Stockholders Equity Requirement after stockholder approval of the conversion of the Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (Series A Preferred Stock) is obtained at its upcoming meeting of the stockholders.
• Readers are cautioned that the Staff may not accept the Companys plan to regain compliance with the Stockholders Equity Requirement.
• Further, even if the Companys Compliance Plan is accepted, the Company may be unable to evidence compliance with the Stockholders Equity Requirement during any extension period that the Staff may grant, either through additional equity financings, improved operational results or shareholder actions.

Industry Context

StockSavvy.ai notes that Nasdaq listing deficiencies related to minimum equity requirements are not uncommon for early-stage or development-stage biotechnology companies. Companies often rely on future financing rounds or strategic events to meet these thresholds. The success of TransCode's plan hinges on shareholder support for a capital-restructuring event.

Stakeholder Impact

• Shareholders: Potential dilution if preferred stock converts, or risk of delisting impacting share value. Shareholder approval is critical.
• Creditors: Delisting could negatively impact the company's ability to secure future financing or service debt.
• Employees: Uncertainty regarding company stability and future operations if delisting occurs.

Next Steps

• Submit a plan to regain compliance with Nasdaq listing rules by July 3, 2026.
• Obtain stockholder approval for the conversion of Series A Preferred Stock at the upcoming stockholder meeting.
• File a definitive proxy statement with the SEC regarding the conversion of preferred stock and other matters.
• Potentially seek additional equity financings if needed to evidence compliance.

Key Dates

Recommendation

The filing highlights a significant risk of delisting due to insufficient equity, which is a serious concern. However, the company has a stated plan to address this through shareholder approval of preferred stock conversion. Until the outcome of the stockholder vote and Nasdaq's review of the compliance plan is known, a 'hold' recommendation is prudent, balancing the immediate risk against the potential for resolution.

Keywords

Nasdaq Listing Rule, Stockholders Equity, Compliance Plan, Series A Preferred Stock, Delisting, Convertible Preferred Stock, SEC Filing, Form 8-K/A